- PR Newswire•3 days ago
Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the first recombinant human protein with the full length 84-amino acid sequence of endogenous parathyroid hormone (PTH). ''As the first and only licensed recombinant parathyroid hormone treatment in Europe for chronic hypoparathyroidism, Natpar represents a historical and timely innovation for patients who cannot be adequately controlled on calcium and vitamin D alone," said Philip J. Vickers, Ph.D., Global Head of Research and Development at Shire.
- Fool.co.uk•4 days ago
These FTSE 100 (INDEXFTSE:UKX) growth stocks could be big winners, says G A Chester.
- Accesswire•4 days ago
Upcoming AWS Coverage on Shire Post-Earnings Results LONDON, UK / ACCESSWIRE / April 25, 2017 / Active Wall St. blog coverage looks at the headline from Eli Lilly and Co. (NYSE: LLY ) as the Company announced ...
SHP.L: Summary for SHIRE PLC ORD 5P - Yahoo Finance
Shire plc (SHP.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
|Bid||4,530.00 x 51000|
|Ask||4,640.00 x 53800|
|Day's range||4,537.00 - 4,678.50|
|52-week range||2,707.19 - 5,377.00|
|PE ratio (TTM)||109.59|
|Dividend & yield||0.26 (0.45%)|
|1y target est||N/A|